Suraksha Diagnostic growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr
Revenue+23.2%
EBITDA+17.4%
Net Income+1.4%
EPS (adj.)+1.2%
Total Assets+34.4%
Total Equity+15.8%
Free Cash Flow−32.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SURAKSHA₹319.55

Suraksha Diagnostic Limited

· Pharma & Health
₹ CrorePeersKRSNAAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,664 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
Revenue+23.2
EBITDA+17.4
Net Income+1.4
EPS (adj.)+1.2
Total Assets+34.4
Total Equity+15.8
Free Cash Flow-32.1
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.